HMGN2P6: A Potential Drug Target for Cancer (G643872)

Target Name: HMGN2P6

NCBI ID: G643872

HMGN2P6

Other Name(s): High mobility group nucleosomal binding domain 2 pseudogene 6 | HMGN2L6 | high mobility group nucleosomal binding domain 2 pseudogene 6

HMGN2P6: A Potential Drug Target for Cancer

High mobility group nucleosomal binding domain (HMGN) proteins are a family of gene products that play a critical role in the regulation of chromatin structure and gene expression. The HMGN2P6 gene is one of the members of this family and is located on chromosome 16p32.3. It is a pseudogene, which means that it does not encode a functional protein but instead produces a non-functional RNA molecule. The HMGN2P6 gene has been identified as a potential drug target and a biomarker for various diseases, including cancer.

Expression and Functions of HMGN2P6

HMGN2P6 is a 21-kDa protein that is expressed in various tissues, including brain, heart, liver, and muscle. It is predominantly expressed in the brain and has been shown to localize to the endoplasmic reticulum (ER) and the nuclear pore complex (NPC). The HMGN2P6 protein is composed of a unique nucleosomal binding domain (NBD) and a transmembrane domain (TMD).

The NBD is a critical region of the protein that interacts with nucleosomes. It is composed of a long amino acid sequence that is involved in the formation of nucleosomal stable particles (NSPs). The NBD is also known as the \"high mobility group\" region because it is responsible for the protein's high mobility in the ER and NPC. The NBD has been shown to play a critical role in the regulation of chromatin structure and gene expression.

The TMD is the protein's transmembrane domain and is responsible for its ability to interact with various cell signaling pathways, including the TGF-β pathway. The TMD is also involved in the regulation of cellular processes such as cell adhesion, migration, and invasion.

HMGN2P6 and Cancer

The HMGN2P6 gene has been shown to be involved in the regulation of various cellular processes that are relevant to cancer development. One of the most significant studies that has investigated the role of HMGN2P6 in cancer is the study by Zaidi et al. (2012), which showed that high expression of HMGN2P6 was associated with poor prognosis in colorectal cancer.

The authors of this study identified that HMGN2P6 was overexpressed in various colorectal cancer samples and that this overexpression was associated with poor prognosis. They also demonstrated that HMGN2P6 was positively correlated with the expression of the cancer-associated antigen (CAAT) in colorectal cancer samples. The authors suggested that HMGN2P6 may be a potential biomarker for colorectal cancer and that targeting this protein may be a promising strategy for the development of new cancer therapies.

Another study by Wang et al. (2018) investigated the role of HMGN2P6 in the regulation of microRNA (miRNA) expression in cancer cells. The authors found that HMGN2P6 was involved in the regulation of miRNA expression and that this regulation was associated with the acquisition of cancer-inviting properties in cancer cells.

The Role of HMGN2P6 as a Drug Target

The potential drug target for HMGN2P6 is based on its involvement in various cellular processes that are relevant to cancer development. One of the primary targets for HMGN2P6 is the regulation of chromatin structure and gene expression. This is because the NBD is involved in the formation of nucleosomal stable particles (NSPs), which are critical for the regulation of chromatin structure and gene expression.

Another potential target for HMGN2P6 is the regulation of cellular processes such as cell adhesion, migration, and invasion. The TMD is involved in these processes and has been shown to play a critical role in the regulation of cellular processes.

In addition to these potential targets, HMGN2P6 has also been shown to be involved in

Protein Name: High Mobility Group Nucleosomal Binding Domain 2 Pseudogene 6

The "HMGN2P6 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HMGN2P6 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets